Connect
To Top

2 Powerful Drugs That May Cure Migraine Could Soon be Available in Your Closest Pharmacy

Existing research shows that in every seven Americans, one suffers from migraines. Unfortunately, the existing medications that are being recommended to cure or even prevent them do not have the desired effects on many people. Drugs like blood-pressure drugs and anti-depressants are fast losing their potency.

But there has been a release of two new research results that people can bank their hopes on, especially those who have not been enjoying the positive results of using migraines drugs which are previously in circulation.

In the latter-stage of clinical experiments, a newly medically birthed type of pill has the power to cut down the attack of migraine recurrence and aggressiveness by 50% in many people.

Existing research shows that in every seven Americans, one suffers from migraines

The two studies which were published in a medical journal during the week, have so much health beneficial news to offer. One of the studies diagnosed the potency of the drug erenumab, which was developed by Novartis in collaboration with Amgen.

In an experiment carried out on 955 people suffering from migraines, there were unfolding of the hidden truth. The second study had 1,130 people on which the test was used to examine the efficacy of Teva Pharmaceutical’s fremanezumab.

Before the trials, the two drugs have been sent to The Food and Drug Administration for approval, and the makers are hoping to begin full production and launching into the market come 2018.

The study took them six months to complete, and in the 6-month period of erenumab study, 43% of the participants used for the trial were administered with a low-intake monthly injection of the drug, and 50% of the patients were given a high-intake monthly injection.

The two categories of patients reported that their migraine regularity and hostility were cut down to approximately 50%. Among all those who were given placebo injection, only an estimated 27% of the people gave feedback on such recovery.

Before the study, the rate at which people complained of migraines disturbances was an average of eight days per month. But the ratio was impaired by 3.2 days for people who use a smaller portion of the drug, and it decreased by 3.7 days for people who received a higher dose, but it was only by 1.8 days for people who got the placebo.

The fremanezumab study tested the two drugs per month and a quarterly injection of the drug against a placebo. Three months later, 41% of people who had used the drug once a month gave feedbacks that their headaches had been cut down by at least 50%, in contrast to only 18% of the people who had used the placebo.

A third group was created, and out of those who had used the injection of the drug only once over the duration of three months, 38% of people sent feedbacks of this kind of recovery.

Two groups that used at least one dose of fremanezumab injection sent feedback of about four and five lesser headache days per month, out of an estimated 13 days at the beginning of the research. People who used three placebo injections sent feedbacks of just 2.5 lesser days of a headache.

The similar feature of both erenumab and fremanezumab are their monoclonal antibody nature, which means that they are drugs produced in the laboratory, and they imitate immune cells in the body by attaching to certain proteins.

Both drugs point at a substance known as calcitonin gene-related peptide (CGRP), which is sent out by the body when a migraine is active. But scientists are not certain about the precise way CGRP affects migraine pain, but there is a suspicion that it changes blood-vessel movement and nerve tingles in the brain. By obstructing this particular peptide, they believe it should decrease or stop migraine attacks.

Part of the information contained in the new studies revealed that antibody therapies are individual-specific, meaning that not everyone will react to it.

A migraine-specific curing medication is a crucial development for patients

Peter also added that these drugs had been produced especially with a goal to get known migraine triggers. He noted that there is a divergence between it and what already exists at present, which are drugs that veered into a migraine from other sources, like epilepsy, blood pressure regulator and depression. Triptan is a type of medication that has been recommended recently for the cure of migraines, and it has already been approved.

The director of neurology at Cincinnati Children’s Hospital Medical Center, Dr. Andrew Hershey, is optimistic that a migraine-specific curing medication is a crucial development for patients. He named CGRP as the “next boondock” in the study of a migraine.

But the good news is that doctors are not relenting in their efforts to find the cause of migraines and Hershey keep the hope alive that more inventions in the area of migraine cure will continue to unfold.

More in Medical Conditions

You must be logged in to post a comment Login

Leave a Reply